Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
about
First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?Novel approaches to target HER2-positive breast cancer: trastuzumab emtansineAutophagy and Apoptotic Crosstalk: Mechanism of Therapeutic Resistance in HER2-Positive Breast CancerHuman epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic optionsTargeted Therapies in HER2-Positive Breast Cancer - a Systematic ReviewTargeted therapy for HER2 positive breast cancerSite-specific functionalization of proteins and their applications to therapeutic antibodiesRole of trastuzumab emtansine in the treatment of HER2-positive breast cancerSerum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patientsProfiling and targeting HER2-positive breast cancer using trastuzumab emtansineHuman epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancerCIViC databaseTheranostic applications of antibodies in oncology.Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?Twenty years of anti-HER2 therapy-associated cardiotoxicityRecent advances in the development of anti-HER2 antibodies and antibody-drug conjugatesCaveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)Efficacy and Safety of HER2-Targeted Agents for Breast Cancer with HER2-Overexpression: A Network Meta-AnalysisAGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2013Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patientsAdo-trastuzumab emtansine-associated telangiectasias in metastatic breast cancer: a case series.Dose-reduced trastuzumab emtansine: active and safe in acute hepatic dysfunctionA multicenter Phase II study evaluating the efficacy, safety and pharmacokinetics of trastuzumab emtansine in Japanese patients with heavily pretreated HER2-positive locally recurrent or metastatic breast cancer.Safety and Efficacy of Trastuzumab Emtansine in Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: a Meta-analysis.Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer.Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancerTrastuzumab emtansine and stereotactic radiosurgery: an unexpected increase in clinically significant brain edema.Trastuzumab emtansine: mechanisms of action and drug resistanceRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.Ado-Trastuzumab Emtansine in Metastatic HER2-Positive Breast Cancer.A pan-cancer proteomic perspective on The Cancer Genome Atlas.Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates.Therapeutic options for HER-2 positive breast cancer: Perspectives and future directionsAGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Radical irradiation of extracranial oligometastases.Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potentialRelationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patients with previously untreated HER2-positive metastatic breast cancer.
P2860
Q26746081-9E612BF5-1A19-437D-93B1-3816C0564F70Q26747729-9103EA70-57ED-47EB-91F2-A8CB242925D8Q26753162-AFE67C46-6D4B-4D8D-BD42-6D5C08EEB0F9Q26777681-C5306D3C-93E7-48A9-8415-EAF570E87CC6Q26777733-D7B3FF7F-31A3-4B0F-9EF7-286CF89136ACQ26830496-6115EE0A-02FD-45EE-8FA8-61EA911A1C12Q26830699-43B3A69F-7906-4090-B50B-C60DB484BAB8Q27003258-5F3D901F-0B49-4C03-B90D-45D7D4F161F3Q27007849-4FEDBE24-36DE-41BB-93EB-C992A80B8488Q27015048-B139D963-514F-4323-974D-386AB42F30E8Q27025863-0C8920ED-1A03-4E56-9983-4E26E8DCC5D2Q27612411-8744B750-1920-48A3-80ED-7FD1D3644859Q27693293-99AE9416-F0EB-42D7-9C59-AB7A01CB9A1CQ27853035-2A49ADA8-7D2D-4163-A985-EE4BC50AA72DQ28067696-23E31E85-9513-4503-A2C9-228DEC22B239Q28079391-54A55D14-FB91-49AE-B24A-2EAFFDC30D85Q28083123-7A06F386-07AD-467F-86B9-CD3E8F1DB02BQ28546477-6CDE14FA-8231-4908-AE0E-AED7100F74ACQ28547354-AF95D0C0-B675-42E4-9C80-DB82B65DD3F7Q30317569-D1014CFA-B7B5-4DC1-96AF-5BE027E8B489Q33414335-D3D147EE-A20A-414C-BDAB-463D577DBABEQ33415375-20FD2E39-EE0F-42E9-943A-DC22130CE13EQ33415915-33DD109E-A1BD-4C26-B79C-9C4200714413Q33421995-B88AE895-4E6F-4E3E-8C48-B92424B5E733Q33430299-68BA7D01-ABC3-49C2-8209-DC3249BC4732Q33430735-803D6622-3B70-4338-8ED6-A0D522F9644DQ33433942-79851A96-2FD3-4F9B-B637-65B65970159EQ33651550-DB0201EC-4BC5-4687-A451-67713CB8619CQ33753475-1CD87DD6-1919-4C9E-B290-E124AAEF1991Q33759627-7B19CA34-9627-4914-B287-E82DEA2ADA9BQ33862786-10663644-BDEB-41D0-8BCF-824516235D66Q33873317-F6058A88-FD3E-4AAF-8550-A372A751C4A1Q33886306-8D4DC30F-33B8-464D-A6D9-937065DA7D80Q33944976-11E32B38-D03D-4967-8A4C-85F3269C99B3Q33954595-523BBC31-CD90-4DC9-A0AE-DB6B3481D8A1Q34023704-BF542C93-1B06-4D12-BEDB-31C795A402CFQ34042768-7BD7C547-C2A8-4F94-8652-5FB20416E6F9Q34124296-F7D74A0A-81D4-411A-9A8C-46E0725C7EA5Q34389275-449C3CB8-E091-4BC2-9BE2-46DA1DB5548BQ34500802-54CC5461-7056-4675-AEAD-AFF7C3ECBDE0
P2860
Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Phase II randomized study of t ...... tive metastatic breast cancer.
@ast
Phase II randomized study of t ...... tive metastatic breast cancer.
@en
Phase II randomized study of t ...... tive metastatic breast cancer.
@nl
type
label
Phase II randomized study of t ...... tive metastatic breast cancer.
@ast
Phase II randomized study of t ...... tive metastatic breast cancer.
@en
Phase II randomized study of t ...... tive metastatic breast cancer.
@nl
prefLabel
Phase II randomized study of t ...... tive metastatic breast cancer.
@ast
Phase II randomized study of t ...... tive metastatic breast cancer.
@en
Phase II randomized study of t ...... tive metastatic breast cancer.
@nl
P2093
P3181
P356
P1476
Phase II randomized study of t ...... tive metastatic breast cancer.
@en
P2093
Barbara Tong
Chunyan Song
Edith A Perez
Ellie Guardino
Giulia V Bianchi
Jeferson Vinholes
Judit Kocsis
Sara A Hurvitz
P304
P3181
P356
10.1200/JCO.2012.44.9694
P407
P577
2013-03-20T00:00:00Z